As VEGF is a major driver of tumor angiogenesis, efforts have focused on novel therapeutics aimed at inhibiting VEGF activity, and antiangiogenic therapies have shown efficacy in treating HCC [3–5]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.